Skip to content

The cost effectiveness of tube feeding versus oral nutritional supplements in hospitalized patients with IBD

The cost effectiveness of tube feeding versus oral nutritional supplements in hospitalized patients with IBD - Tube feeding study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON33890
Enrollment
60
Registered
2009-04-10
Start date
2009-07-16
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bowel Disease Inflammatory Bowel Disease

Interventions

Feeding Group A will receive standard treatment with liquid oral nutritional supplements (nutri-drink, 4 times 200ml - 4 times 300kcal - per day). Group B will recieve standard therapy combined with
100ml = 100kcal).

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: · Endoscopically or histologically proven Crohn*s disease or ulcerative colitis before 3 months prior to randomization · Age 18-70 years · Written informed consent · Adequate contraception for males and females during treatment and follow up (written confirmation) · All therapy is permitted concomitant therapy · Patients must be hospitalized

Exclusion criteria

Exclusion criteria: · Pregnancy, breast-feeding · Any other condition which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in and completing the study · Total parental nutrition · Bowel perforation · Short bowel · Neoplastic condition of the subject

Design outcomes

Primary

MeasureTime frame
The reduction of hospital stay in days of 30%

Secondary

MeasureTime frame
Quality of life and psychopathology by psychological assessment using the IBDQ questionnaire

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)